Immunic Therapeutics has closed a private placement that could provide up to $400 million to support the company’s Phase 3 clinical program of vidofludimus calcium in multiple sclerosis (MS) and help fund its transition into a commercial-stage company as it prepares for potential regulatory approval of the…
vidofludimus calcium
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a…
Recommended Posts
- One silent MRI lesion may be enough to consider stronger MS treatment
- It may only be one life with multiple sclerosis, but it’s mine
- Certain cannabis-based therapies may help relieve spasticity in MS
- Greater disability tied to poorer cognitive function in people with RRMS
- FDA OKs first clinical trial testing novel oral therapy in MS patients